Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action

dc.contributor.authorMarais B.J.
dc.contributor.authorRaviglione M.C.
dc.contributor.authorDonald P.R.
dc.contributor.authorHarries A.D.
dc.contributor.authorKritski A.L.
dc.contributor.authorGraham S.M.
dc.contributor.authorEl-Sadr W.M.
dc.contributor.authorHarrington M.
dc.contributor.authorChurchyard G.
dc.contributor.authorMwaba P.
dc.contributor.authorSanne I.
dc.contributor.authorKaufmann S.H.
dc.contributor.authorWhitty C.J.
dc.contributor.authorAtun R.
dc.contributor.authorZumla A.
dc.date.accessioned2011-05-15T16:18:12Z
dc.date.available2011-05-15T16:18:12Z
dc.date.issued2010
dc.description.abstractThe Millennium Development Goal target for tuberculosis control is to halt the spread of tuberculosis by 2015, and begin to reverse the worldwide incidence. After the introduction of standard control practices in 1995, 36 million people were cured and about 6 million deaths were averted. However, substantial scientific advances and innovative solutions are urgently needed together with creative new strategies. Strong international and national political commitment is essential. Urgent action is needed by national governments to fund their own programmes, and for the G8 countries and other donor governments and organisations to support governmental and non-governmental efforts. To foster the global need for urgent action to control the tuberculosis epidemic, The Lancet, in collaboration with the Stop TB Partnership, WHO, Global Fund to Fight AIDS, Tuberculosis and Malaria, and the experts participating in this Series, is launching The Lancet TB Observatory, which will assess and monitor progress in tuberculosis control and research, assess domestic and global financing, regularly disseminate information, and advocate for intensified efforts with stakeholders at all levels. © 2010 Elsevier Ltd. All rights reserved.
dc.description.versionReview
dc.identifier.citationThe Lancet
dc.identifier.citation375
dc.identifier.citation9732
dc.identifier.issn01406736
dc.identifier.other10.1016/S0140-6736(10)60554-5
dc.identifier.urihttp://hdl.handle.net/10019.1/14558
dc.subjectantiretrovirus agent
dc.subjectBCG vaccine
dc.subjectcotrimoxazole
dc.subjectisoniazid
dc.subjectrifampicin
dc.subjecttuberculostatic agent
dc.subjectacquired immune deficiency syndrome
dc.subjectbacterial transmission
dc.subjectdirectly observed therapy
dc.subjectepidemic
dc.subjectfunding
dc.subjecthealth care delivery
dc.subjecthealth care financing
dc.subjecthealth care system
dc.subjecthealth service
dc.subjecthuman
dc.subjectHuman immunodeficiency virus infection
dc.subjectinfection prevention
dc.subjectinformation dissemination
dc.subjectmedical research
dc.subjectmixed infection
dc.subjectmultidrug resistance
dc.subjectpoint of care testing
dc.subjectprevalence
dc.subjectpriority journal
dc.subjectresearch priority
dc.subjectreview
dc.subjectsputum smear
dc.subjecttuberculosis
dc.subjecttuberculosis control
dc.subjectAIDS-Related Opportunistic Infections
dc.subjectFinancial Support
dc.subjectHealth Priorities
dc.subjectHealth Services
dc.subjectHumans
dc.subjectResearch
dc.subjectTuberculosis
dc.subjectWorld Health
dc.titleScale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action
dc.typeReview
Files